Zusammenfassung
Urologika werden zur Behandlung von Miktionsstörungen im weitesten Sinne angewandt, denen Störungen der Blase und – bei Männern – der Prostata sowie verschiedene andere urologische Erkrankungen zugrunde liegen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alhasso AA, McKinlay J, Patrick K, Stewart L (2006): Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003193
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmastser R (2010): Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 (13):1192–1202
Boyle P, Gould AL, Roehrborn CG (1996): Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405
Bundesministerium für Gesundheit (2015): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage IX – Festbetragsgruppenbildung Anlage X – Aktualisierung von Vergleichsgrößen, Urologische Spasmolytika, Gruppe 1, in Stufe 3 nach § 35 Absatz 1 des Fünften Buches Sozialgesetzbuch (SGB V) vom 15. Oktober 2015 veröffentlicht am Mittwoch, 2. Dezember 2015 BAnz AT 02.12.2015 B2
Chapple CR (1996): Selective a1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29: 129–144
Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N (2013): Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63: 296–305
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group (2004): Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int. 93: 303–310
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group (2011): Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 59: 342–352
Djavan B, Marberger M (1999): A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1–13
Grünewald V (2005): Pharmakologische Therapie von neurogenen Harnblasenfunktionsstörungen. In: Truß MC et al: Pharmakotherapie in der Urologie. Springer Medizin Verlag Heidelberg, S.383–311
Haab F, Stewart L, Dwyer P (2004): Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45: 420–429
Harvey M-A, Baker K, Wells GA (2003): Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185: 56–61
Hay-Smith J, Herbison P, Ellis G, Morris A (2005): Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005; 3: CD005429
Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB and the Prospective European Doxazosin and Combination Therapy Study Investigators (2003): Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PRE-DICT) trial. Urology 61: 119–126
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ (2012): Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan 18; 1: CD005429
Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K (1999): A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84: 646–651
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003): The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398
Milani S, Djavan B (2005): Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95 (Suppl 4): 29–36
Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group (2004): Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Brit J Urol Int 93: 311–318
Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ (2014): Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol 65: 79–95
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006): Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011): Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108: 388–394
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ; European Association of Urology (2013): EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64: 118–140
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group (2010): The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57: 123–131
Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA (1998): Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16 (suppl): S48–S61
Thompson IM, Goodman PJ, Tangen CM, Lucia M.S., Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan BA, Szczepanek CM, Ceowley JJ, Coltman CA (2003): The Influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M (2015): Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Rev Endocr Metab Disord 16: 177–198
Tsujii T (2000): Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7: 199–205
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag GmbH Germany
About this chapter
Cite this chapter
Mühlbauer, B., Oßwald, H. (2017). Urologika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_45
Download citation
DOI: https://doi.org/10.1007/978-3-662-54630-7_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54629-1
Online ISBN: 978-3-662-54630-7
eBook Packages: Medicine (German Language)